Every cagrilintide-vs-retatrutide number is a cross-trial comparison
Why the difference between real and knockoff semaglutide is so critical Watch the video to learn more
About Noom Noom is the digital healthcare company empowering people to live better, longer lives
NEWS Correction 30 June 2025 Obesity drugs made in China could power next wave of treatments Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 52 print issues and online access 199,00 per year only 3,83 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Nature 643 , 315-316 (2025) doi: Updates & Corrections Correction 30 June 2025 : An earlier version of this story misnamed the US Food and Drug Administration
The Novo Nordisk spokesperson said the FDA alert does not relate to the companys products, Ozempic or Wegovy, but pertains to compounded semaglutide products, which are not approved in Canada nor in the U.S